@article{1a752124f3cc4bd0b7fca75dc19c253a,
title = "Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma",
abstract = "Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.",
keywords = "Biomarker, Fibroblast growth factor receptor, Hyperphosphatemia, Infigratinib, Pharmacodynamics, Pharmacokinetics, Response rate, Urothelial carcinoma",
author = "Yung Lyou and Petros Grivas and Rosenberg, {Jonathan E.} and Jean Hoffman-Censits and Quinn, {David I.} and {P. Petrylak}, Daniel and Matthew Galsky and Ulka Vaishampayan and {De Giorgi}, Ugo and Sumati Gupta and Howard Burris and Jessica Rearden and Ai Li and Hao Wang and Maribel Reyes and Susan Moran and Siamak Daneshmand and Dean Bajorin and Pal, {Sumanta K.}",
note = "Publisher Copyright: {\textcopyright} 2020",
year = "2020",
month = dec,
doi = "10.1016/j.eururo.2020.08.002",
language = "English",
volume = "78",
pages = "916--924",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "6",
}